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OBJECTIVES: This study investigated whether the serum matrix metalloproteinase-9 level is an independent
predictor of recurrence after catheter ablation for persistent atrial fibrillation.
METHODS: Fifty-eight consecutive patients with persistent atrial fibrillation were enrolled and underwent
catheter ablation. The serum matrix metalloproteinase-9 level was detected before ablation and its relationship
with recurrent arrhythmia was analyzed at the end of the follow-up.
RESULTS: After a mean follow-up of 12.1±7.2 months, 21 (36.2%) patients had a recurrence of their arrhythmia
after catheter ablation. At baseline, the matrix metalloproteinase-9 level was higher in the patients with
recurrence than in the non-recurrent group (305.77±88.90 vs 234.41±93.36 ng/ml, respectively, p=0.006).
A multivariate analysis showed that the matrix metalloproteinase-9 level was an independent predictor of
arrhythmia recurrence, as was a history of atrial fibrillation and the diameter of the left atrium.
CONCLUSION: The serum matrix metalloproteinase-9 level is an independent predictor of recurrent arrhythmia
after catheter ablation in patients with persistent atrial fibrillation.
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’ INTRODUCTION
Catheter ablation is the most promising treatment for atrial
fibrillation (AF). The multiple procedure success rate of
pulmonary vein isolation (PVI) for paroxysmal AF is
approximately 80% after long-term follow-up (1,2). However,
the success rates of PVI for persistent AF are low, ranging
from 45%-60% (3,4). Recurrences are common after an initial
procedure for persistent AF ablation and repeat ablation is
often required to maintain freedom from AF (5). Thus, both
the outcome and the cost-effectiveness of the ablation
procedure are less favorable for persistent than paroxysmal
AF. Non-invasive predictors for AF recurrence after catheter
ablation are necessary to select the optimal patients for this
procedure.
Atrial fibrosis contributes to both electrical and structural
atrial remodeling and thrombogenesis in patients with AF.
Recent studies have shown that inflammation plays an
important role in atrial fibrosis (6,7). Inflammation may also
affect the prognosis of patients with AF treated by catheter
ablation. In our previous study, a variant of the IL6R gene
conferred a risk of AF recurrence after catheter ablation in a
Chinese Han population (8). Matrix metalloproteinase-9
(MMP-9), which is a novel fibrotic and inflammatory marker,
is correlated with the progression of AF (9). Therefore, we
hypothesized that the serum MMP-9 level can also predict
recurrence after catheter ablation for persistent AF. In this
study, we observed the relationship between the serum
MMP-9 level and arrhythmia recurrence after catheter
ablation for persistent AF.
’ MATERIAL AND METHODS
Participants
This study recruited 58 consecutive patients (age 55.8±7.9
years, 31 (53.4%) males) with drug-refractory persistent AF
who intended to undergo catheter ablation. All patients hadDOI: 10.6061/clinics/2016(05)02
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documented, recorded, persistent AF. Persistent AF was dia-
gnosed according to the guidelines (10). Patients with structural
heart disease; hematological, renal, or hepatic impairment;
inflammation; neoplastic disorders; recent (o3 months) myo-
cardial infarction or stroke; acute AF precipitated by thyrotox-
icosis; or any acute infection were excluded. Ethical approval
was granted by the Institutional Review Board of Renmin
Hospital of Wuhan University. All subjects gave written
informed consent.
Blood sampling and echocardiography
The day before catheter ablation, the serum MMP-9 level
was detected and trans-esophageal echocardiography (TEE)
was performed.
The method used to detect the serum MMP-9 level was
described elsewhere (11). Briefly, blood samples were obtained
by a peripheral venipuncture and were centrifuged at 3,200  g
for 10 minutes at approximately 4oCwithin an hour of collection.
The serum was separated into aliquots and stored at -80oC until
personnel blinded to the patients’ clinical information performed
the analysis. The serum MMP-9 levels were determined using
commercial standardized in vitro enzyme-linked immunosorbent
assay (ELISA) methods according to the manufacturer’s instruc-
tions (RayBiotech INC, Atlanta, Georgia, USA). The intra- and
inter-assay coefficients of variation for the assay wereo10% and
o12%, respectively.
The left atrial diameter (LAD), left ventricular diameter
(LVD) and left ventricular ejection fraction (LVEF) were
measured by TEE.
Catheter ablation for persistent AF
The ablation procedure was performed under local
anesthesia. Patients were heparinized to maintain an
activated clotting time over 300 s. The atrial anatomy was
reconstructed with the CARTO system (Biosense-Webster
Inc., Diamond Bar, CA, USA) or NavX mapping system
(St. Jude Medical, St. Paul, MN). The ablation procedure
comprised the following steps: 1) PVI and 2) linear ablation
at the left atrial mitral isthmus and, if the AF was not
terminated, the left atrial roof. Additional linear ablation,
including the left atrium posterior wall line, right atrium
isthmus line and SVC isolation line, was added if the AF was
not terminated after steps 1 and 2. The endpoint of the
procedure was AF termination. If the AF still did not stop
after additional linear ablation, sinus rhythm was restored by
electrical cardioversion.
According to the 2012 HRS/EHRA/ECAS expert con-
sensus statement on catheter and surgical ablation of AF,
any atrial tachycardia (AT), atrial flutter (AFL) or AF episode
lasting longer than 30 seconds should be considered recurrence
at three months post-ablation (5).
Follow-up
All patients were routinely followed up in the outpatient
department by cardiologists every month. If patients
complained about palpitations, fatigue, or other symptoms
related to arrhythmia, Holter monitoring was performed.
Patients were also advised to see their doctor anytime they
had these symptoms to undergo a 12-lead ECG examination
or 24-hour Holter monitoring. In asymptomatic patients,
24-hour Holter monitoring or 7-day cardiac event recording
was performed every three months after the procedure.
The endpoint for follow-up was documented recurrence of
AT/AFL/AF lasting longer than 30 seconds.
Statistical analysis
All continuous variables are expressed as the means ± SD
and categorical variables are expressed as proportions. Between-
group comparisons were performed using the two-sample t-test
or w2 test as appropriate. Age, sex and variables with po0.1
in the univariate analysis were selected for inclusion in a
logistic regression multivariate analysis. The cutoff points
for MMP-9 were identified by a receiver operating character-
istic (ROC) curve. Statistical significance was established
at po0.05. The rates of freedom from AT/AFL/AF were
determined and compared using a Kaplan-Meier analysis
and log-rank test. The statistical analysis was performed
using SPSS software (version 17.0; SPSS Inc., Chicago, IL).
’ RESULTS
Baseline characteristics
After a mean follow-up of 12.1±7.2 months, 21 (36.2%)
patients had developed AT/AFL/AF recurrence after cathe-
ter ablation. The baseline characteristics of the patients with
or without recurrence are shown in Table 1. There were no
significant differences in the age, sex, body mass index
(BMI), hypertension, LVD, LVEF, or drug use between the
two groups. However, patients with recurrent arrhythmia
had a longer history of AF, larger LAD and higher serum
MMP-9 levels compared with the non-recurrent group.
Ablation procedure and electrical cardioversion
We retrospectively analyzed the procedure-related data for
the non-recurrent and recurrent patients. The rates of AF
termination in steps 1, 2 and 3 in the two groups were not
significantly different. The only difference between the two
groups in terms of the ablation procedure was the use of left
atrium roof line ablation. In that stage, the non-recurrent and
recurrent groups both had four patients who converted to SR
(10.8% vs 19.0%, respectively, p=0.036) (Table 2).
Six patients in the non-recurrent group and 4 patients in
the recurrent group (16.2% vs 23.8%, respectively p=0.150)
who did not covert to SR after total ablation underwent
electrical cardioversion (Table 2).
Logistic multivariate analysis
In the logistic multivariate analysis, the MMP-9 levels,
AF history and LAD were independent predictors of AF
recurrence after catheter ablation for persistent AF (Table 3).
Based on the ROC curve, an MMP-9 level 4279.36 ng/ml
predicted AF recurrence after ablation of persistent AF with a
sensitivity of 71.4% and a specificity of 70.3% (area under the
ROC curve =0.70). We therefore used 279.36 ng/ml as the
cutoff point for the MMP-9 level. The AT/AFL/AF-free
survival after catheter ablation, as determined by the Kaplan-
Meier curves, showed that there were different AT/AFL/AF
survival periods for groups of patients with different MMP-9
levels (Figure 1).
’ DISCUSSION
In the present study, we prospectively explored the
predictive value of the MMP-9 level for recurrent arrhythmia
after catheter ablation. We found that patients with persistent
AF who had high baseline MMP-9 levels had an increased
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rate of recurrence. The MMP-9 level independently predicted
AT/AFL/AF recurrence.
The mechanism underlying AF is complex and AF is often
caused by multiple factors (12). Atrial myocytes and fibrotic
changes of the connective extracellular matrix (ECM) are
both involved in the progression of AF. Fibrosis is caused by
an imbalance between the degradation and deposition of the
cardiac ECM, representing a nonspecific response to cardi-
omyocyte necrosis or apoptosis. MMPs, which are a multi-
gene family of structurally and functionally homogeneous
proteolytic enzymes, regulate ECM turnover and may have a
determinant role in the atrial structural remodeling involved
in the development and perpetuation of AF(13). Previous
experimental studies showed that MMP-9 plays a key role
in cardiac remodeling and contributes to chamber dilation
and excessive collagen accumulation in both aging hearts
and hearts post-myocardial infarction (14,15). Recently,
MMP-9 was found to have a close relationship with the
initiation and perpetuation of AF. Huxley et al. reported
that elevated levels of MMP-9 are independently associated
with an increased risk of AF (16). Notably, the level of
MMP-9 was correlated with the development of AF. In the
progression of idiopathic AF, the MMP-9 levels gradually
increased from paroxysmal AF through persistent AF to
permanent AF (17). Furthermore, previous studies also
showed that MMP-9 is associated with atrial remodeling in
AF patients.
Nakano et al. (18) first demonstrated the close relationship
between MMP-9 and AF. They showed that increased
expression of MMP-9 may contribute to atrial structural
remodeling and atrial dilatation during AF. MMP-9 also
participates in atrial remodeling after catheter ablation.
Additionally, a significant up-regulation of MMP-9 is asso-
ciated with a greater reduction in the left atrial size (19). In our
study, the MMP-9 levels in patients with persistent AF were
similar to the previously reported data (16,17). The patients
who developed recurrence had a higher serum MMP-9 level,
indicating more severe atrial remodeling and advanced AF.
These speculations were confirmed by the longer history of
AF and larger LAD in this group.
The efficacy of catheter ablation for patients with
persistent AF remains unsatisfactory. Despite adopting new
techniques, recent studies have reported that up to 40% of
patients have relapsed tachycardia after the initial procedure
(20,21). Which patient characteristics can be used to evaluate
their prognosis has remained unclear. Various candidates for
predicting AF recurrence after catheter ablation have been
reported, including age, gender, BMI, ECG, the echocardio-
graphic findings, observations made using cardiovascular
magnetic resonance (CMR) and some serum or plasma
factors (22-25). Some of these studies conflict and the most
precise predictors of recurrence after persistent AF ablation
remain uncertain. AF progresses with the aggravation of
fibrosis and inflammation. Different inflammatory factors
cause focal necrosis of the myocardium, modulate ion
channel functionality and then initiate the structural and
electrical remodeling of the atrium. MMP-9 is one marker of
the fibrosis and inflammation that is associated with atrial
remodeling in patients with AF. Elevated levels of MMP-9
are related to the occurrence and maintenance of AF in
patients with persistent AF (26). In this study, we investi-
gated the factors that influence the outcomes of persistent AF
ablation. Because the ablation and electrical cardioversion
data in the two groups (high/low MMP-9) were not
significantly different, the different outcomes were not due
to differences in the ablation procedure. We observed that
traditionally reported factors, such as the AF history and
LAD, were also significantly associated with the recurrence
of AF. In addition, we found that the serumMMP-9 level was
an independent predictor of recurrence. In previous studies,
Table 1 - Baseline characteristics of the patients with and without recurrence.
Non-recurrent (N=37) Recurrent (N=21) p value
Age (years) 54.4±6.9 58.3±7.6 0.057
Gender, male 21 (56.8) 11 (52.3) 0.819
Body mass index (kg/m2) 26.3±5.2 27.8±6.4 0.336
AF history (months) 44.6±16.5 54.6±17.9 0.036
Hypertension 5 (13.5) 3 (14.2) 0.888
LAD (mm) 38.6±7.9 45.1±9.4 0.007
LVDD (mm) 51.6±8.3 53.1±7.1 0.490
LVEF (%) 57.1±8.3 57.9±9.6 0.740
ACEI/ARB 7 (18.9) 3 (14.2) 0.358
Amiodarone (n, %) 19 (51.4) 12 (57.1) 0.740
BB (n, %) 34 (91.9) 19 (90.5) 0.995
MMP-9 (ng/ml) 234.41±93.36 305.77±88.90 0.006
Values are given as the No. (%) or means±SD.
Table 2 - Procedure-related data for the patients with and without recurrence.
Non-recurrent (N=37) Recurrent (N=21) p value
Step 1: PVI 7 (18.9) 3 (14.3) 0.329
Step 2: linear ablation of the left atrium 16 (43.2) 12 (57.1) 0.295
left isthmus line 12 (32.4) 8 (38.1) 0.549
left roof line 4 (10.8) 4 (19.0) 0.036
Steps 1 + 2 23 (62.2) 15 (71.4) 0.606
Step 3: additional linear ablation 14 (37.8) 6 (28.5) 0.329
All three steps 31 (83.8) 28 (76.2) 0.082
Electrical cardioversion 6 (16.2) 4 (23.8) 0.150
Values are given as the No. (%). Additional lines included the left atrium posterior wall line, the right atrium isthmus line and the SVC isolation line.
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the reported changes in the MMP-9 levels in patients with
paroxysmal AF were inconsistent and various diseases may
cause inflammation and increase the levels of inflammatory
factors. Thus, the patients enrolled in our study were all
confirmed to have persistent AF without structural heart
disease to eliminate this bias. Our data showed that the
serum MMP-9 level was effective in predicting recurrence in
this AF cohort.
The MMP superfamily comprises many members. In
addition to MMP-9, several other members (MMP-2, MMP-
3 AND MMP-7) and tissue inhibitors of MMPs (TIMPs), such
as TMP1-3, also have a strong association with the incidence
of AF (11,27). In the present study, we focused on MMP-9, so
the other MMPs/TIMPs are candidates for further study.
Whether any of these MMPs/TIMPs (or their combinations)
are also indicators of the risk of AF recurrence after catheter
ablation remains of interest.
Our findings may be helpful to select which patients with
persistent AF should undergo catheter ablation. Because the
MMP-9 level is correlated with atrial fibrosis and predicts AF
relapses, it may also represent a therapeutic target. Inhibition
of the MMPs and regulation of the extracellular collagen
matrix might be useful therapeutically in patients with AF.
Gene deletion or pharmacological inhibition of MMP activity
attenuates atrial remodeling and decreases the vulnerability
to AF (28-30). In the TIPTOP trial, the MMP tissue inhibitor
doxycycline was used short-term in patients with acute
myocardial infarction and left ventricular dysfunction. The
trial results showed that doxycycline therapy inversely
correlated with the six-month infarct size and severity and
left ventricular dilation (31). No clinical trials regarding the
use of MMP tissue inhibitors to treat AF have been reported.
A prospective randomized trial to determine the value of the
MMP-9 level in predicting AF recurrence and to assess the
effects of an MMP tissue inhibitor on persistent AF may be
warranted.
The patients enrolled in this study were a special AF cohort.
Atrial fibrosis is correlated with the development of AF. Post-
mortem biopsies, electroanatomical mapping studies and
delayed-enhancement CMR images have demonstrated that
Table 3 - The results of the multivariate analysis and the 95%
confidence intervals for recurrent atrial fibrillation.
p value Odds ratio 95% confidence interval
Age (years) 0.394 0.981 0.863-1.102
AF history (months) 0.038 1.243 1.082-1.427
LAD (mm) 0.017 1.225 1.024-1.443
MMP-9 (ng/ml) 0.029 1.136 1.018-1.273
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Figure 1 - The rates of freedom from AT/AFL/AF, as determined by a Kaplan-Meier analysis. The recurrence rate was higher among
patients with a baseline MMP-9 4279.36 ng/ml.
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there is more extensive fibrosis in patients with persistent AF
than paroxysmal AF. In patients with permanent AF, the
fibrosis is more extensive than in those with persistent AF
(32-37). Permanent AF usually co-exists with structural heart
disease, which may aggravate fibrosis and inflammation.
In recent guidelines, catheter ablation is not recommended
for patients with permanent AF. The present study only
evaluated patients with persistent AF without underlying
structural disease, which might limit its generalizability.
The serum MMP-9 level was higher in patients with
recurrence, and it was identified as an independent predictor
of arrhythmia relapse after catheter ablation in patients with
persistent AF.
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